Long-term antiretroviral treatment outcomes in seven countries in the Caribbean

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 4, 2012, Pages

  Koenig, Serena P ^a,b   Rodriguez, Luis A ^c   Bartholomew, Courtenay ^d   Edwards, Alison ^e   Carmichael, Tracie E ^f   Barrow, Geoffrey ^g   Cabié, André ^h   Hunter, Robert ⁱ   Vasquez Mora, Giselle ^j   Quava Jones, Avion ^d   Adomakoh, Nicholas ^f   Figueroa, J Peter ^k   Liautaud, Bernard ^h   Torres, Magaly ⁱ   Pape, Jean W ^a,e  

^a Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c COPRESIDA ^*  (Dominican Republic)

^d Medical Research Foundation   (Trinidad and Tobago)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f Ministry of Health   (Barbados)

^g UNIVERSITY HOSPITAL OF THE WEST INDIES   (Jamaica)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

ⁱ SCHOOL OF MEDICINE   (Puerto Rico)

^j Universidad Autónoma de Santo Domingo   (Dominican Republic)

^k UNIVERSITY OF THE WEST INDIES   (Jamaica)

more..

Author keywords

Antiretroviral therapy; Caribbean; HIV; HIV AIDS; Low and middle income countries; Tuberculosis

Indexed keywords

ANTIVIRUS AGENT; HEMOGLOBIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; CARIBBEAN ISLANDS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTI-RETROVIRAL AGENTS; BODY WEIGHT; CARIBBEAN REGION; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMORBIDITY; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84859761443     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318245d3c1     Document Type: Article

References (62)

1. UNAIDS, World Health Organization. AIDS Epidemic Update. Geneva, Switzerland: UNAIDS; 2009.
2. Pan American Health Organization, World Health Organization. Health conditions and trends. In: Health in the Americas, 2007. Volume I-Regional. Washington, DC: PAHO; 2007:58-207.
3. Nadai Y, Eyzaguirre LM, Sill A, et al. HIV-1 epidemic in the Caribbean is dominated by subtype B. PLoS One. 2009;4:e4814.
4. HIV Epidemiology and Field Services Program. HIV/AIDS in New York City, 2001-2007. New York, NY: Department of Health and Mental Hygiene; 2009.
5. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342.
6. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41:217-224. (Pubitemid 40962502)
7. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet. 2008;371:1603-1611. (Pubitemid 351626844)
8. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325-2334. (Pubitemid 41713744)
9. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1- infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367: 817-824.
10. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793. (Pubitemid 44223102)
11. Toure S, Kouadio B, Seyler C, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22:873-882. (Pubitemid 351563837)
12. Madec Y, Laureillard D, Pinoges L, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS. 2007;21:351-359. (Pubitemid 46175047)
13. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS. 2008;22:2303-2311.
14. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-1189. (Pubitemid 43786107)
15. Laurent C, Ngom Gueye NF, Ndour CT, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005;38:14-17. (Pubitemid 40094112)
16. Auld AF, Mbofana F, Shiraishi RW, et al. Four-year treatment outcomes of adult patients enrolled in mozambique's rapidly expanding antiretroviral therapy program. PLoS One. 2011;6:e18453.
17. Sanne IM, Westreich D, Macphail AP, et al. Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc. 2009;12:38.
18. Leger P, Charles M, Severe P, et al. 5-year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med. 2009; 361:828-829.
19. Bekker LG, Myer L, Orrell C, et al. Rapid scale-up of a communitybased HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006;96: 315-320.
20. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010;24:563-572.
21. Nglazi MD, Lawn SD, Kaplan R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr. 2011; 56:e1-e8.
22. Thai S, Koole O, Un P, et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health. 2009;14:1048-1058.
23. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med. 2009;151: 241-251; W-252.
24. Ferradini L, Laureillard D, Prak N, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS. 2007;21:2293-2301. (Pubitemid 350287455)
25. Van der Borght SF, Clevenbergh P, Rijckborst H, et al. Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa. Antivir Ther. 2009; 14:63-74.
26. Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS. 2008;22:2291-2302.
27. Corey DM, Kim HW, Salazar R, et al. Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr. 2007;44:451-455. (Pubitemid 46555381)
28. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895. (Pubitemid 38553709)
29. Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363-1370. (Pubitemid 34722068)
30. Wolff MJ, Cortes CP, Shepherd BE, et al. Long-term outcomes of a national expanded access program to antiretroviral therapy: the Chilean AIDS cohort. J Acquir Immune Defic Syndr. 2010;55:368-374.
31. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298.
32. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(Suppl 1):1-15.
33. Ekouevi DK, Balestre E, Ba-Gomis FO, et al. Low retention of HIVinfected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health. 2010;15(Suppl 1):34-42.
34. Kilaru KR, Kumar A, Sippy N, et al. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Med. 2006;7: 99-104.
35. Tuboi SH, Schechter M, McGowan CC, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr. 2009;51:615-623.
36. UNAIDS. Report on the Global AIDS Epidemic 2010. Geneva, Switzerland: UNAIDS; 2010.
37. UNAIDS. The Status of HIV in the Caribbean. Geneva, Switzerland: UNAIDS; 2010.
38. International Monetary Fund. World economic outlook database. Available at: http://www.imf.org/external/pubs/ft/weo/2011/02/weodata/index.aspx. Accessed May 13, 2011.
39. UNAIDS. AIDS Info. Available at: http://www.unaids.org/globalreport/ AIDSinfo.htm. Accessed May 13, 2011.
40. Republique d'Haiti Programme National de Lutte contre le Sida. Rapport de Situation Nationale a L'intention de L'ungass, Janvier 2008-Décembre 2009. 2010.
41. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva, Switzerland: WHO; 2006.
42. Maskew M, MacPhail P, Menezes C, et al. Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J. 2007;97:853-857. (Pubitemid 47542654)
43. Bisson GP, Gaolathe T, Gross R, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One. 2008;3: e1725.
44. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resourcelimited settings: systematic review and meta-analysis. PLoS One. 2009; 4:e5790.
45. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376: 449-457.
46. Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviraltreated patients in sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis. 2009;48:115-122.
47. Lanoy E, May M, Mocroft A, et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS. 2009;23: 2199-2208.
48. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2011.
49. Keiser O, Anastos K, Schechter M, et al. Antiretroviral therapy in resource- limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health. 2008;13:870-879. (Pubitemid 351813514)
50. Bartholomew C, Boyce G, Fraser O, et al. Late Presentation of HIV/AIDS Patients: a Caribbean problem. AIDS Patient Care STDS. 2011.
51. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents Recommendations for a Public Health Approach 2010 Revision. Geneva, Switzerland: WHO; 2010.
52. Hawkins C, Chalamilla G, Okuma J, et al. Gender differences in antiretroviral treatment outcomes among HIV-infected adults in Dar es Salaam, Tanzania. AIDS. 2011.
53. Larsen MV, Omland LH, Gerstoft J, et al. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide populationbased cohort study. Addiction. 2010;105:529-535.
54. Baez-Feliciano DV, Quintana R, Gomez MA, et al. Trends in the HIV and AIDS epidemic in a Puerto Rican cohort of patients: 1992-2005. Bol Asoc Med P R. 2006;98:174-183.
55. Malta M, Bastos FI, da Silva CM, et al. Differential survival benefit of universal HAART access in Brazil: a nation-wide comparison of injecting drug users versus men who have sex with men. J Acquir Immune Defic Syndr. 2009;52:629-635.
56. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86:559-567. (Pubitemid 351931216)
57. World Bank. World Bank list of economies. Available at: http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS.Accessed November 21, 2011.
58. Dalal RP, Macphail C, Mqhayi M, et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr. 2008;47: 101-107. (Pubitemid 351619376)
59. Brinkhof MW, Spycher BD, Yiannoutsos C, et al. Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS One. 2010;5:e14149.
60. Fox MP, Brennan A, Maskew M, et al. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010;15:405-413.
61. Yu JK, Chen SC, Wang KY, et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ. 2007;85:550-554. (Pubitemid 47041634)
62. Krebs DW, Chi BH, Mulenga Y, et al. Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia. AIDS Care. 2008;20:311-317. (Pubitemid 351451247)